Berkeley Heights-based Chugai Pharma USA LLC, a subsidiary of Tokyo, Japan-based Chugai Pharmaceutical Co. Ltd., announced Friday the appointment of Athos Gianella-Borradori, M.D. as the chief medical officer of CPUSA.
According to the announcement, Dr. Gianella-Borradori has more than 20 years of experience in international drug research and development. He’s held senior level positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland), and Clavis Pharma (Norway).
He is responsible for all clinical activity in the U.S. He represents CPUSA in relationships with the FDA, academia, clinical investigators and patient communities, CPUSA said. He is also responsible for increasing the awareness of the company’s achievements.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy